Navigation Links
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. In November 2012, Omeros announced that OMS302 met the co-primary efficacy endpoints in this second pivotal Phase 3 clinical trial by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period.

This multicenter, double-blind, Phase 3 clinical trial enrolled 416 patients randomized 1:1 to receive either OMS302 or placebo. Safety data were collected through postoperative day 90. In this Phase 3 clinical trial, OMS302 was well tolerated. The incidence of adverse events was similar between the two treatment groups, and the adverse event profile was similar to that seen in prior OMS302 clinical trials. No safety concerns have been identified in the OMS302 clinical development program. Results from this study are expected to be presented at an upcoming major ophthalmology meeting. Omeros also plans to publish the results in a leading peer-reviewed ophthalmology journal.

"While these data were expected, they underscore the safety benefits of intraoperative and local delivery of OMS302 – administration of efficacious and low concentrations of the active ingredients directly to the surgical site reduces systemic uptake an
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
2. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
3. Omeros is Not Aware of Any Justification for Share Price Movement
4. Omeros Corporation Reports Third Quarter 2012 Financial Results
5. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
6. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
7. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
8. Omeros to Present at Two Upcoming Conferences
9. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
10. Omeros Corporation Reports Second Quarter 2012 Financial Results
11. Omeros Announces Discovery in MASP-2 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  The Green Exchange, ... the world,s first HIPAA compliant mobile app that connects ... farm-to-table fresh medical marijuana, announced today that their service ... Unlike Eaze, Meadow and more than half a dozen ... last year, Loud Cannabis is unique in that it ...
(Date:7/2/2015)... 2015   Decision Resources Group finds ... less frequent dosing as the highest unmet need ... burden on both patients and providers associated with ... injections, which are the current standard of care. ... is in development for dosing every two to ...
(Date:7/2/2015)... June 25, 2015 ... announced the addition of the "2015 ... Global Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in Clinical Chemistry and Immunodiagnostics: ... a new seven-country strategic analysis of major ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... ... tumors, SEATTLE, ... for advanced, metastatic prostate cancer has been,androgen-deprivation therapy. That is, the ... via,surgical castration (orchiectomy) or medical castration with,testosterone-blocking drugs. While such therapy ...
... Cell Lung Cancer, WASHINGTON, June 2 Today, ... from the pivotal Phase,III First Line in Lung Cancer ... Society of Clinical Oncology (ASCO), showed a,significant increase in ... non-small cell lung cancer (NSCLC)., "This is very ...
Cached Medicine Technology:Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 3Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 4Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data 2
(Date:7/4/2015)... ... ... hacker gains access to someone’s email account, it can lead to all sorts of trouble, ... FTC issued a scam alert about a social engineering scam which cons a target ... by the hacker. All they have to do is click for a password reset ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... Dori Friend opened registration for a new SEO training system called "Page ... guide for organic traffic generation has received glowing reviews from several well-known marketers. ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... its new expansion of the Pharmacogenomics Research Network (PGRN), ... Children,s Research Hospital a prestigious grant to focus on ... million grant is titled "PAAR4KidsPharmacogenomics of Anticancer Agents Research ... for 10 years. But now, we will be the ...
... Clinical trials in a variety of areas within interventional ... will directly affect the way that people with cardiovascular ... presented exclusively at TCT, will lead to new treatments ... Among the topics being covered are stenting in the ...
... being fed a poor diet of biscuits, ice-cream and soft ... in the journal Nutrition & Dietetics found some ... sugar foods, despite health authorities recommending exclusive breastfeeding to six ... tracked 587 women from two Perth maternity hospitals through regular ...
... The United States must focus on conserving the use ... from rapidly rising rates of antibiotic-resistant infections, according to ... nation,s supply of antibiotics is being depleted by resistance, ... that they no longer respond to widely-used treatments. Most ...
... pilot study suggests the hallucinogen psilocybin may be feasible ... and anxiety, with promising effects on mood, according to ... the January 2011 print issue of Archives of ... "In recent years, there has been a growing awareness ...
... and about one-fifth of fathers in the United Kingdom appear ... and 12th year of age, with the highest rates in ... online today that will appear in the November print issue ... of the JAMA/Archives journals. "Depression in parents is associated ...
Cached Medicine News:Health News:St. Jude researcher receives grant to focus on cancer pharmacogenomics in children 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 3Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 4Health News:What are babies made of? Research shows for some it is sugar, salt and not all things nice 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety 2Health News:Parents at highest risk for depression in the first year after child's birth 2
... Offers one-handed operation for stent ... reduce unintentional stent movement. Allows user ... vessel wall apposition. Maintains tactile feel ... ,MicroMarker technology aids in visualization at ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
... Q-Pulse is the UK's market-leading ... over 250 pathology laboratories in the ... Q-Pulse. In addition, hundreds of pathology ... Kong, South Africa and the United ...
Medicine Products: